TY - JOUR
T1 - Anti-biofilm peptides can rescue fluconazole and amphotericin B efficacies against Candida albicans
AU - Kissmann, Ann Kathrin
AU - Mildenberger, Vanessa
AU - Krämer, Markus
AU - Alpízar-Pedraza, Daniel
AU - Martell-Huguet, Ernesto M.
AU - Perez-Erviti, Julio A.
AU - Cetinkaya, Ahmet
AU - Pietrasik, Joanna
AU - Otero-Gonzalez, Anselmo J.
AU - Firacative, Carolina
AU - Rodríguez, Armando
AU - Ständker, Ludger
AU - Weil, Tanja
AU - Stenger, Steffen
AU - Rosenau, Frank
N1 - © 2025. The Author(s).
PY - 2025/7/9
Y1 - 2025/7/9
N2 - Candida albicans infections are a global health thread and challenge healthcare environments due to acquired resistances against prominent antifungals like amphotericin B and fluconazole, which additionally have severe adverse effects. The peptide Pom-1 originally isolated from the freshwater mollusk Pomacea poeyana, and its derivatives Pom-1 A-F have proven their potential against biofilms of clinical C. albicans isolates and were suspected to act without candidolytic pore-formation. Here, Pom-1 and its derivatives were shown to act as neutralizing antimicrobial peptides (nAMPs) inhibiting cell-cell interactions and hence biofilm formation. Combining Pom-1 nAMPs with fluconazole and amphotericin B restored their efficacy against resistant C. albicans isolates. Addition of Pom-1 nAMPs allowed to reduce required concentrations to 10–50% below their described effective therapeutic doses. This opens doors not only to mitigate adverse effects of fluconazole and amphotericin B therapies, but also towards novel combination therapies against C. albicans as a severe re-emerging pathogen.
AB - Candida albicans infections are a global health thread and challenge healthcare environments due to acquired resistances against prominent antifungals like amphotericin B and fluconazole, which additionally have severe adverse effects. The peptide Pom-1 originally isolated from the freshwater mollusk Pomacea poeyana, and its derivatives Pom-1 A-F have proven their potential against biofilms of clinical C. albicans isolates and were suspected to act without candidolytic pore-formation. Here, Pom-1 and its derivatives were shown to act as neutralizing antimicrobial peptides (nAMPs) inhibiting cell-cell interactions and hence biofilm formation. Combining Pom-1 nAMPs with fluconazole and amphotericin B restored their efficacy against resistant C. albicans isolates. Addition of Pom-1 nAMPs allowed to reduce required concentrations to 10–50% below their described effective therapeutic doses. This opens doors not only to mitigate adverse effects of fluconazole and amphotericin B therapies, but also towards novel combination therapies against C. albicans as a severe re-emerging pathogen.
UR - https://www.mendeley.com/catalogue/2004c56b-0eec-3110-ad69-b730d010a9e6/
U2 - 10.1038/s41598-025-10315-4
DO - 10.1038/s41598-025-10315-4
M3 - Research Article
C2 - 40634492
AN - SCOPUS:105010266749
SN - 2045-2322
VL - 15
SP - 24593
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 24593
ER -
